{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:40:02Z","timestamp":1748274002335,"version":"3.41.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>In December 2022, federal regulations in the US changed to increase access to buprenorphine for patients who need treatment for opioid use disorder (OUD), removing the requirement for prescribers to obtain a DATA waiver. This study\u2019s purpose was to evaluate the impact of these changes in regulations on buprenorphine prescribing for OUD at a community teaching hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-center, retrospective cohort study investigated buprenorphine prescribing habits before and after the requirement for a DATA waiver was removed. The study focused on patients who had a diagnosis code for OUD or had buprenorphine with or without naloxone ordered for OUD from March 1 to December 20, 2022 (before the changes) and from March 1 to December 20, 2023 (after the changes). The primary outcome was the percentage of patients with OUD who received buprenorphine with or without naloxone before and after the changes in regulations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 386 patients for whom charts were reviewed, 162 patients met the inclusion criteria: 81 patients in the before group and 81 patients in the after group. Before the changes in regulations, 40% of patients with OUD had buprenorphine ordered in the inpatient setting, compared to 63% of patients after regulations were changed (P = 0.003). More patients had their home buprenorphine regimen continued in the inpatient setting in the after group than in the before group (53% vs 37%; P = 0.04).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After removal of the DATA waiver requirement for buprenorphine prescribing, more patients with OUD were prescribed buprenorphine during hospitalization and at discharge.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf035","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:24:53Z","timestamp":1741134293000},"page":"S2943-S2950","source":"Crossref","is-referenced-by-count":0,"title":["The impact of change in regulations on buprenorphine prescribing for opioid use disorder"],"prefix":"10.1093","volume":"82","author":[{"given":"Evon","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Trinity Health Oakland Hospital , Pontiac, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"DeHoff","sequence":"additional","affiliation":[{"name":"Trinity Health Oakland Hospital , Pontiac, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lambart","sequence":"additional","affiliation":[{"name":"Trinity Health Oakland Hospital , Pontiac, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Bray","sequence":"additional","affiliation":[{"name":"Trinity Health Oakland Hospital , Pontiac, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Marogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"author":"Department","key":"2025052611015163700_CIT0001"},{"key":"2025052611015163700_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J Addict Med"},{"volume-title":"Cleveland Clinic.","key":"2025052611015163700_CIT0003"},{"key":"2025052611015163700_CIT0004","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee","year":"2018","journal-title":"Am J Prev Med"},{"key":"2025052611015163700_CIT0005","article-title":"Buprenorphine","volume-title":"StatPearls [proprietary data]","author":"Kumar","year":"2023"},{"issue":"8","key":"2025052611015163700_CIT0006","doi-asserted-by":"crossref","first-page":"e2014045","DOI":"10.1001\/jamanetworkopen.2020.14045","article-title":"Monthly patient volumes of buprenorphine-waivered clinicians in the US","volume":"3","author":"Duncan","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025052611015163700_CIT0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.10.002","article-title":"Prescribing patterns of buprenorphine waivered physicians","volume":"181","author":"Thomas","year":"2017","journal-title":"Drug Alcohol Depend"},{"volume-title":"Substance Abuse and Mental Health Administration","key":"2025052611015163700_CIT0008"},{"volume-title":"Buprenex","year":"2023","key":"2025052611015163700_CIT0009"},{"issue":"2","key":"2025052611015163700_CIT0010","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/ADM.0000000000001066","article-title":"Identifying barriers to buprenorphine treatment for patients with opioid use disorder among anesthesiologists and pain practitioners: a survey study","volume":"17","author":"John","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"2025052611015163700_CIT0011","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpainsymman.2022.05.004","article-title":"Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care","volume":"64","author":"Ho","year":"2022","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"2025052611015163700_CIT0012","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.japh.2023.06.001","article-title":"Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act","volume":"63","author":"Adams","year":"2023","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"2025052611015163700_CIT0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jac5.1579","article-title":"Pharmacists\u2019 role in buprenorphine management for opioid use disorder: a narrative review","volume":"5","author":"Cleary","year":"2022","journal-title":"J Am Coll Clin Pharm"},{"issue":"7","key":"2025052611015163700_CIT0014","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf035\/62245740\/zxaf035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/Supplement_3\/S2943\/62245740\/zxaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/Supplement_3\/S2943\/62245740\/zxaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:01:58Z","timestamp":1748271718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/Supplement_3\/S2943\/8051333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":14,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2025,3,4]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf035","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,6,1]]},"published":{"date-parts":[[2025,3,4]]}}}